MBX Biosciences
Clinical trials sponsored by MBX Biosciences, explained in plain language.
Biotech developing peptide therapies for endocrine and metabolic disorders.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New obesity drug MBX 4291 enters first human safety trial Results expected Oct 2026 (estimated)
- New Once-Weekly shot shows promise for Long-Term hypoparathyroidism control Results expected May 2027 (estimated)
-
New shot aims to stop dangerous sugar crashes after gastric bypass
Disease control CompletedThis study tests a new drug called MBX 1416 in 10 people who have low blood sugar episodes after weight loss surgery. Participants receive two injections of the drug, a low dose and a high dose, about two weeks apart. The goal is to see if the drug can raise the lowest blood suga…
Phase 2 • Sponsor: MBX Biosciences • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Weekly shot could cut calcium pills for rare hormone disorder
Disease control CompletedThis study tested a new medicine called MBX 2109, given once a week as a shot, in 64 adults with hypoparathyroidism. The goal was to see if it could safely help patients reduce their daily calcium and vitamin D pills while keeping blood calcium levels normal. The trial was comple…
Phase 2 • Sponsor: MBX Biosciences • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
Kidney function key to new Drug's safety
Knowledge-focused CompletedThis study looked at how the experimental drug MBX 2109 is handled by the body in people with different levels of kidney function. 25 adults with normal or impaired kidneys received a single dose. The goal was to measure safety and drug levels, not to treat a disease. Results wil…
Phase 1 • Sponsor: MBX Biosciences • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:55 UTC